

Noisy-Or Risk Allocation: A Probabilistic Model for Attributable Risk Estimation

Amelia J. Averitt, MPH MA PhD^{1,2}; Adler Perotte, MD MA²

1. Regeneron Genetics Center, Clinical Informatics. Tarrytown, NY.
2. Columbia University, Department of Biomedical Informatics. New York, NY.






risks are an important tool for
the understanding and communication of
exposure-outcome relationships





attributable risk (AR) estimation


proportion of
outcome (O)
attributable to
exposure (E)





attributable risk (AR) estimation

proportion of
outcome (O)
attributable to
exposure (E)




=

“excess risk” Levin, 1953

$$AR = \frac{P(O) - P(O|\neg E)}{P(O)}$$




attributable risk (AR) estimation





attributable risk (AR) estimation





attributable risk (AR) estimation
the setting of binary exposures and outcomes



attributable risk (AR) estimation

the setting of binary exposures and outcomes

calculation of excess risk Levin,
1953

$$AR = \frac{P(D) - P(D|\neg E)}{P(D)}$$

approximation using
disproportionality methods Bate,
2002

- multi-gamma Poisson shrinker (MGPS)
- risk ratios (RR)

$$AR = \frac{RR - 1}{RR}$$

regression-based methods
Hayashi, 2018; Caster, 2007

- penalized logistic regression



attributable risk (AR) estimation

the setting of binary exposures and outcomes

calculation of excess risk Levin, 1953

$$AR = \frac{P(D) - P(D|\neg E)}{P(D)}$$

approximation using
disproportionality methods Bate, 2002

- multi-gamma Poisson shrinker (MGPS)
- risk ratios (RR)

$$AR = \frac{RR - 1}{RR}$$

regression-based methods Hayashi, 2018; Caster, 2007

- penalized logistic regression

① global inference

② local inference

③ account for confounding



attributable risk (AR) estimation

the setting of binary exposures and outcomes

calculation of excess risk Levin, 1953

$$AR = \frac{P(D) - P(D|\neg E)}{P(D)}$$

approximation using
disproportionality methods Bate, 2002

- multi-gamma Poisson shrinker (MGPS)
- risk ratios (RR)

$$AR = \frac{RR - 1}{RR}$$

regression-based methods Hayashi, 2018; Caster, 2007

- penalized logistic regression



global inference



local inference



account for confounding



attributable risk (AR) estimation

the setting of binary exposures and outcomes

calculation of excess risk Levin, 1953

$$AR = \frac{P(D) - P(D|\neg E)}{P(D)}$$

approximation using disproportionality methods Bate, 2002

- multi-gamma Poisson shrinker (MGPS)
- risk ratios (RR)

$$AR = \frac{RR - 1}{RR}$$

regression-based methods Hayashi, 2018; Caster, 2007


- penalized logistic regression

1 global inference

2 local inference

3 account for confounding



 a model that meets
all of these criteria
is preferred

attributable risk (AR) estimation

the setting of binary exposures and outcomes

calculation of excess risk Levin,
1953

$$AR = \frac{P(D) - P(D|\neg E)}{P(D)}$$

approximation using
disproportionality methods Bate,
2002

- multi-gamma Poisson shrinker (MGPS)
- risk ratios (RR)

$$AR = \frac{RR - 1}{RR}$$

regression-based methods
Hayashi, 2018; Caster, 2007

- penalized logistic regression


① global inference

② local inference



③ account for confounding




Noisy-Or Risk Allocation (NORA) Model




Noisy-Or Risk Allocation (NORA) Model



Noisy-Or Risk Allocation (NORA) Model




Noisy-Or Risk Allocation (NORA) Model






Noisy-Or Risk Allocation (NORA) Model






Noisy-Or Risk Allocation (NORA) Model



Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

exposure k for person n

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

outcome for person n


$R_k \sim \text{Beta}(\alpha, \beta)$

risk for exposure k

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k} R_k)$

activation of exposure k for person n

Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

exposure k for person n

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

outcome for person n


$R_k \sim \text{Beta}(\alpha, \beta)$

risk for exposure k

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k}R_k)$

activation of exposure k for person n

Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

exposure k for person n

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

outcome for person n


$R_k \sim \text{Beta}(\alpha, \beta)$

risk for exposure k

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k} R_k)$

activation of exposure k for person n

Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

exposure k for person n

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

outcome for person n


$R_k \sim \text{Beta}(\alpha, \beta)$

risk for exposure k

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k}R_k)$

activation of exposure k for person n

Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

exposure k for person n

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

outcome for person n

$R_k \sim \text{Beta}(\alpha, \beta)$


risk for exposure k

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k} R_k)$

activation of exposure k for person n

- R & Z learned by Gibbs sampling

Noisy-Or Risk Allocation (NORA) Model



Nodes \rightarrow variables

Edges \rightarrow relationships between variables

● \rightarrow observed

○ \rightarrow unobserved

N = number of people

K = number of exposures

$X_{n,k} \sim \text{Bernoulli}(\epsilon)$

$Y_n = \begin{cases} 1 & \text{if any } Z_k = 1 \\ 0 & \text{if all } Z_k = 0 \end{cases}$

$R_k \sim \text{Beta}(\alpha, \beta)$

$Z_{n,k} \sim \text{Bernoulli}(X_{n,k}R_k)$

exposure k for person n


outcome for person n

risk for exposure k


activation of exposure k for person n

- R & Z learned by Gibbs sampling
- α & β learned by Metropolis Hastings


Noisy-Or Risk Allocation (NORA) Model




- through activations (Z) we can infer which exposures are causal for one patient and a one outcome (**local inferences**)



Noisy-Or Risk Allocation (NORA) Model




- through activations (Z) we can infer which exposures are causal for one patient and a one outcome (**local inferences**)




- use Z 's to infer the attributable risks for an exposure causing an outcome (**global inferences**)

Noisy-Or Risk Allocation (NORA) Model



- through activations (Z) we can infer which exposures are causal for one patient and a one outcome (**local inferences**)




- use Z 's to infer the attributable risks for an exposure causing an outcome (**global inferences**)
- multivariate setting **accounts for confounding!**


- ① a simulation in which the ground truth is known
- ② application to real-world clinical data

- ① a simulation in which the ground truth is known
- ② application to real-world clinical data


SIMULATION



SIMULATION




SIMULATION




SIMULATION → EVALUATION

Censored Model

 $p(\text{MI} \mid \text{high LDL, family hx})$ 

Uncensored Model

 $p(\text{MI} \mid \text{high LDL, obesity, sedentary, family hx})$ 

1 correctness of implementation

2 robustness to bias

SIMULATION → RESULTS

1. correctness of implementation → recover the true attributable risk of High LDL ($p=0.30$)

Risk of MI from high LDL

	NORA	LR
Censored Model	0.21	0.44
Uncensored Model	0.30	0.50

← ground truth = 0.30

SIMULATION → RESULTS

1. correctness of implementation → recover the true attributable risk of High LDL ($p=0.30$)

Risk of MI from high LDL

	NORA	LR
Censored Model	0.21	0.44
Uncensored Model	0.30	0.50

← ground truth = 0.30

2. robustness to bias → how close are estimates of High LDL attributable risks to the ground truth when backdoor paths are not observed?

Bias in high LDL estimate

	NORA	LR
% bias Censored vs Truth	30.5%	46.6%
% bias Uncensored vs Truth	1.3%	66.7%


← less biased when backdoor paths are *unobserved*

← less biased when backdoor paths are *observed*

- ① a simulation in which the ground truth is known
- ② application to real-world clinical data

APPLICATION TO CLINICAL DATA

1. create noisy, observational cohorts to investigate a single outcome
2. apply NORA and comparators to learn ARs of exposures for outcome
 - Levin 1953 calculation
 - disproportionality analyses (MGPS-EGBM & RR)
 - penalized logistic regression (L1)



exposure-outcome relationship	outcome
condition – condition	heart failure kidney disease renal impairment disorder of the spleen Kaposi sarcoma glaucoma
procedure – condition	mucositis hypothyroidism
drug – adverse drug reaction	hearing loss mucositis

APPLICATION TO CLINICAL DATA → EVALUATION

APPLICATION TO CLINICAL DATA → EVALUATION

demonstrate **global inference of risk** over high AR exposures from NORA versus the high AR exposures from the comparators

- compare AR estimates from literature vs estimates from NORA and comparators → Kaposi Sarcoma

APPLICATION TO CLINICAL DATA → EVALUATION

demonstrate **global inference of risk** over high AR exposures from NORA versus the high AR exposures from the comparators

- compare AR estimates from literature vs estimates from NORA and comparators → Kaposi Sarcoma

demonstrate **local inference of outcome** over AR estimates from NORA and comparators

- predictive performance (AUROC) of NORA vs L1 and comparators on a held-out dataset

demonstrate **local inference of risk** over high AR exposures from NORA for an individual.

- choose a patient with outcome, simulate activations using exposures and risks learned from model → Heart Failure

APPLICATION TO CLINICAL DATA → RESULTS → global inference of risk

KAPOSI SARCOMA - a rare type of cancer that is most commonly seen in the HIV/AIDS patients, but is occasionally seen in HIV-negative populations of severely immunocompromised patients. Angeletti, 2008

	NORA	L1	Levin 1953	RR	MGPS-EBGM
Human immunodeficiency virus infection	0.0070	0.7872	0.2022	0.9566	0.9603

APPLICATION TO CLINICAL DATA → RESULTS → global inference of risk

KAPOSI SARCOMA - a rare type of cancer that is most commonly seen in the HIV/AIDS patients, but is occasionally seen in HIV-negative populations of severely immunocompromised patients. Angeletti, 2008

	NORA	L1	Levin 1953	RR	MGPS-EBGM	Gold-Standard Liu, 2015
Human immunodeficiency virus infection	0.0070	0.7872	0.2022	0.9566	0.9603	0.0048

APPLICATION TO CLINICAL DATA → RESULTS → global inference of risk

KAPOSI SARCOMA - a rare type of cancer that is most commonly seen in the HIV/AIDS patients, but is occasionally seen in HIV-negative populations of severely immunocompromised patients. Angeletti, 2008

	NORA	L1	Levin 1953	RR	MGPS-EBGM	Gold-Standard Liu, 2015
Human immunodeficiency virus infection	0.0070	0.7872	0.2022	0.9566	0.9603	0.0048

APPLICATION TO CLINICAL DATA → RESULTS → local inference of outcome

Outcome
disseminated intravascular coagulation
glaucoma
hearing loss
heart failure
Kaposi sarcoma
mucositis (exposures drugs)
renal impairment
splenomegaly
hypothyroidism
mucositis (exposures procedures)

APPLICATION TO CLINICAL DATA → RESULTS → local inference of outcome


Outcome	AUROC	
	NORA	L1
disseminated intravascular coagulation	0.8878	0.7773
glaucoma	0.7017	0.6999
hearing loss	0.5056	0.6329
heart failure	0.8030	0.7953
Kaposi sarcoma	0.8011	0.5624
mucositis (exposures drugs)	0.5291	0.6560
renal impairment	0.8170	0.7965
splenomegaly	0.6248	0.5000
hypothyroidism	0.5643	0.6349
mucositis (exposures procedures)	0.5829	0.6134

APPLICATION TO CLINICAL DATA → RESULTS → local inference of outcome

Outcome	AUROC	
	NORA	L1
disseminated intravascular coagulation	0.8878	0.7773
glaucoma	0.7017	0.6999
hearing loss	0.5056	0.6329
heart failure	0.8030	0.7953
Kaposi sarcoma	0.8011	0.5624
mucositis (exposures drugs)	0.5291	0.6560
renal impairment	0.8170	0.7965
splenomegaly	0.6248	0.5000
hypothyroidism	0.5643	0.6349
mucositis (exposures procedures)	0.5829	0.6134

APPLICATION TO CLINICAL DATA → RESULTS → local inference of risk

APPLICATION TO CLINICAL DATA → RESULTS → local inference of risk



Significance

- NORA identifies a cohesive set of high-AR risk factors that have reasonable estimates of risk.
- Simulations suggest that the model may be more robust to confounding than logistic regression.
- NORA support global and local inferences, which helps us rectify care of a single patient with public-health.

Significance

- NORA identifies a cohesive set of high-AR risk factors that have reasonable estimates of risk.
- Simulations suggest that the model may be more robust to confounding than logistic regression.
- NORA support global and local inferences, which helps us rectify care of a single patient with public-health.

Limitations

- violation of causal independence
- we make certain distributional choices
- may learn patterns in EHR documentation rather than true causes
 - complicated by assumption that timestamps are correct
- unseen confounders

Funding

This research is supported by grants
R01LM009886-10 and T15LM007079 from
The National Library of Medicine.

Thank you. Questions?



amelia.averitt@regeneron.com



<http://ajaveritt.com>



<https://www.linkedin.com/in/ameliajaveritt>



[@AJAveritt](https://twitter.com/AJAveritt)